6-K
Avricore Health Inc. (AVCRF)
UNITED STATES
SECURITIESAND EXCHANGE COMMISSION
Washington,D.C. 20549
Form6-K
REPORTOF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of February, 2023.
Commission File Number: 000-51848
AvricoreHealth Inc.
(Exact name of registrant as specified in its charter)
1120-789 West Pender St, Vancouver, BC, V6C 1H2
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): NO
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): NO
Note: Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Exhibits
The following exhibits are included in this form 6-K:
| Exhibit<br> No. | Description | Date<br> Released |
|---|---|---|
| 1 | News<br> Release- AVRICORE HEALTH CORPORATE UPDATE – EARNINGS ADVISORY 2022 AND 2023 OBJECTIVES | February<br> 01, 2023 |
| 2 | News<br> Release- AVRICORE HEALTH MAKES THE GRADE ON 2023 TSX VENTURE 50 | February<br> 21, 2023 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AVRICORE HEALTH INC. | ||
|---|---|---|
| Date:<br> March 10, 2023 | By | “Kiki Smith” |
| Kiki Smith | ||
| Chief Financial Officer |
Exhibit1
AVRICOREHEALTH CORPORATE UPDATE – EARNINGS ADVISORY 2022 AND 2023 OBJECTIVES
VANCOUVER, BRITISH COLUMBIA – February 01, 2023 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) is entering the second year of a multi-year growth plan to bring HealthTab, its turnkey solution for point of care testing and data management, to more pharmacies across Canada and the world. As part of this effort the Company is pleased to provide insight into the successes of last year and lay out updates and objectives on further progress.
“Last year we set out bold targets and today we can demonstrate we’ve been able to achieve them,” said Hector Bremner, CEO of Avricore Health Inc. “There’s no doubt that we are poised for significant growth in 2023 and beyond.”
RecordEarnings
If innovation was easy, everyone would do it. But at Avricore we know the future of pharmacy has arrived and they need the tools to deliver the services needed to better manage minor ailments and chronic disease. That’s why HealthTab’s incubation and development over the past few years has been so important and supported with investment by the Company.
In 2022 HealthTab went into the revenue phase, successfully piloting and scaling to more than 420 locations by the end of 2022 thanks to Shoppers Drug Mart and Loblaws and instrument partners, Abbott.
This means the Company realized record unaudited revenues for the year ending 2022 of just over $2,000,000. HealthTab, as the subsidiary, realized a profit of approximately $420,000. The Company will begin its annual audit soon, with expected completion before the end of April.
Whatyou need to know: We expect revenues earned largely in the later half of any given year, as was the case in 2022. However, the Company expects to see strong year-over-year revenue growth in 2023.
FocusedGrowth
In 2022 the Company achieved not only record revenues, but a fiscal discipline which has allowed it to grow in a sustainable manner. The entire Avricore team is committed to maintaining that discipline, ensuring revenues and assets are deployed in a targeted fashion.
Specifically, the Company anticipates further asset acquisitions to support further HealthTab growth, additional staff to support customer needs and API connections with key digital partners.
Whatyou need to know: The Company does not currently have plans to raise equity but use cashflow and commercial debt vehicles to support growth.
InfectiousDisease
In collaboration with Abbott and Shoppers Drug Mart, the Company is now preparing to deploy 100 Abbott ID Now^™^ instruments with the objective of delivering the instrument’s strep tests. This will be the first fully cloud-connected network of such analyzers in pharmacy, delivering on-site molecular tests for virus and real-time insights into treated populations.
TheYear Ahead
Avricore Health anticipates an exciting year ahead, with many indications of policy and funding support for pharmacy. Much of this is still in progress now, however these items are the focus for the year:
| 2023<br> Objectives |
|---|
| Further<br> expansion of HealthTab with current partners |
| Expansion<br> of HT in other pharmacy groups in Canada |
| International<br> expansion |
| Hiring<br> key positions to support technical and business development efforts |
| Revenue<br> growth and profitability |
HealthTab™Market Fast Facts
| ● | Point<br> of Care Testing Market to reach $93.21 Billion USD in 2030 (Source) |
|---|---|
| ● | Nearly<br> 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed<br> (Source) |
| ● | Over<br> 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source) |
| ● | Close<br> to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often<br> it’s only after a heart attack they are diagnosed. (Source) |
| ● | There<br> are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in<br> the UK. |
AboutHealthTab™
HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.
AboutAvricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company’s mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.
Contact:
AvricoreHealth Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com
CautionaryNote Regarding Forward-Looking Statements:
Information in this press release that involves Avricore Health’s expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neitherthe TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy
Exhibit 2
AVRICORE HEALTH MAKES THE GRADE ON 2023 TSX VENTURE 50
VANCOUVER, BRITISH COLUMBIA – February 21, 2023 – AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “AVCR”) has been honoured by being named as one of the 2023 Venture 50, the TSX Venture Exchange’s list of top performing companies.
“To make the Venture 50 feels great and the whole team is excited to keep delivering on our promise to build the world’s largest rapid-testing network in pharmacy,” said Hector Bremner, CEO of Avricore Health. “Thank you to all our partners and supporters for helping us make this dream of success become a reality!”
Avricore was selected out of over 1700 businesses currently listed on the TSX Venture Exchange for its stellar growth in market capitalization, share price appreciation and trading volume. Driving these results is the scale up and expansion of HealthTab^™^, the Company’s point-of-care testing platform, which is on track to becoming the world’s largest, most reliable network in community pharmacies.
The Company’s current plans are expected to see HealthTab in hundreds of new locations and even new countries, which is expected to drive significant increases in revenues. This means last year’s successes will continue to be the trend.
To hear more about this exciting story, visit www.avricore.com and see our TSX Venture 50 video here.
HealthTab™Market Fast Facts
| ● | Point<br> of Care Testing Market to reach $93.21 Billion USD in 2030 (Source) |
|---|---|
| ● | Nearly<br> 13.6 Million Canadians expected to be diabetic or prediabetic by 2030, with many undiagnosed<br> (Source) |
| ● | Over<br> 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source) |
| ● | Close<br> to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often<br> it’s only after a heart attack they are diagnosed. (Source) |
| ● | There<br> are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in<br> the UK. |
AboutHealthTab™
HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.
The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams
including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.
AboutAvricore Health Inc.
Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the Company’s mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.
Contact:
AvricoreHealth Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com
CautionaryNote Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health’s expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as “outlook,” “will,” “could,” “would,” “might,” “remains,” “to be,” “plans,” “believes,” “may,” “expects,” “intends,” “anticipates,” “estimate,” “future,” “positioned,” “potential,” “project,” “remain,” “scheduled,” “set to,” “subject to,” “upcoming,” and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company’s expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health’s management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore’s public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.
Neitherthe TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) acceptsresponsibility for the adequacy or accuracy